# Thomas Kaley

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thomas-kaley/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,372 |
| Field | Glioma Diagnosis and Treatment |
| h-index | 44 |
| i10-index | 71 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5042155392 |
| ORCID iD | https://orcid.org/0000-0002-2540-8518 |
| Works | 251 |

## Researcher papers

- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [OncoKB: A Precision Oncology Knowledge Base](https://scholariq.org/papers/oncokb-a-precision-oncology-knowledge-base/)
- [Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma](https://scholariq.org/papers/neoadjuvant-anti-pd-1-immunotherapy-promotes-a-survival-benefit-with/)
- [Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/central-nervous-system-cancers-version-3-2020-nccn-clinical-practice-guidelines/)
- [Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma](https://scholariq.org/papers/randomized-phase-ii-and-biomarker-study-of-pembrolizumab-plus-bevacizumab-versus/)
- [NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017](https://scholariq.org/papers/nccn-guidelines-insights-central-nervous-system-cancers-version-1-2017/)
- [NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022](https://scholariq.org/papers/nccn-guidelines-insights-central-nervous-system-cancers-version-2-2022/)

## Researcher topics

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CNS Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/cns-lymphoma-diagnosis-and-treatment/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.